Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience

Background: Subcutaneous infliximab and vedolizumab formulations have been developed for maintenance therapy in inflammatory bowel disease. The objective of this study was to explore the inflammatory bowel disease patient’s acceptance for switching from intravenous infliximab or vedolizumab to subcu...

Descripción completa

Detalles Bibliográficos
Autores principales: Remy, Clotilde, Caron, Bénédicte, Gouynou, Celia, Haghnejad, Vincent, Jeanbert, Elodie, Netter, Patrick, Danese, Silvio, Peyrin-Biroulet, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781002/
https://www.ncbi.nlm.nih.gov/pubmed/36555913
http://dx.doi.org/10.3390/jcm11247296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781002/
https://www.ncbi.nlm.nih.gov/pubmed/36555913
http://dx.doi.org/10.3390/jcm11247296

Ejemplares similares